Bamco Inc. NY Has $23.06 Million Stock Position in Repligen Co. (NASDAQ:RGEN)

Bamco Inc. NY cut its position in shares of Repligen Co. (NASDAQ:RGEN - Free Report) by 4.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 160,227 shares of the biotechnology company's stock after selling 6,792 shares during the quarter. Bamco Inc. NY owned 0.29% of Repligen worth $23,063,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Bayesian Capital Management LP acquired a new stake in shares of Repligen during the 4th quarter worth approximately $947,000. Algert Global LLC acquired a new stake in shares of Repligen during the 4th quarter valued at about $844,000. Alyeska Investment Group L.P. bought a new stake in Repligen in the fourth quarter valued at about $53,428,000. Itau Unibanco Holding S.A. bought a new stake in Repligen in the fourth quarter valued at about $40,000. Finally, Utah Retirement Systems raised its position in Repligen by 1.1% in the fourth quarter. Utah Retirement Systems now owns 9,294 shares of the biotechnology company's stock worth $1,338,000 after purchasing an additional 100 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors.

Insider Activity at Repligen

In other news, Director Margaret Pax acquired 250 shares of the firm's stock in a transaction that occurred on Monday, March 17th. The stock was purchased at an average price of $150.69 per share, for a total transaction of $37,672.50. Following the completion of the acquisition, the director now owns 1,043 shares in the company, valued at $157,169.67. This trade represents a 31.53 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. 1.20% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on RGEN. Canaccord Genuity Group lowered their price target on Repligen from $170.00 to $150.00 and set a "hold" rating on the stock in a research report on Wednesday, April 16th. Evercore ISI began coverage on shares of Repligen in a research report on Tuesday, March 18th. They set an "in-line" rating and a $155.00 target price for the company. Wolfe Research upgraded shares of Repligen from a "peer perform" rating to an "outperform" rating and set a $160.00 price target on the stock in a research report on Tuesday, April 29th. TD Cowen assumed coverage on shares of Repligen in a research note on Monday, February 10th. They set a "buy" rating and a $200.00 price objective on the stock. Finally, JPMorgan Chase & Co. cut their target price on shares of Repligen from $200.00 to $190.00 and set an "overweight" rating for the company in a research note on Tuesday, April 29th. Six investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $173.25.

Repligen Trading Down 3.6 %

Repligen stock traded down $4.61 during mid-day trading on Friday, hitting $123.24. The stock had a trading volume of 580,989 shares, compared to its average volume of 727,651. The stock has a 50-day simple moving average of $135.03 and a two-hundred day simple moving average of $145.37. The company has a current ratio of 10.44, a quick ratio of 8.76 and a debt-to-equity ratio of 0.26. The stock has a market capitalization of $6.92 billion, a PE ratio of -241.65, a P/E/G ratio of 4.54 and a beta of 1.21. Repligen Co. has a 12 month low of $102.97 and a 12 month high of $182.52.

Repligen (NASDAQ:RGEN - Get Free Report) last issued its quarterly earnings results on Tuesday, April 29th. The biotechnology company reported $0.39 EPS for the quarter, topping the consensus estimate of $0.35 by $0.04. The company had revenue of $169.17 million during the quarter, compared to analysts' expectations of $163.65 million. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. Repligen's revenue was up 10.4% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.28 EPS. As a group, sell-side analysts forecast that Repligen Co. will post 1.72 EPS for the current year.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.